Engineering strategies to optimise adoptive cell therapy in ovarian cancer

Advanced ovarian cancer has traditionally been associated with a poor prognosis with 5-year survival rates of approximately 30%. Recent advances in targeted therapies, specifically poly (ADP-ribose) polymerase inhibitors (PARPi), have significantly improved the prognosis for some patients, however, treatments are limited to biomarker defined subgroups. New treatments for the remainder, and for those who fail targeted therapy, are urgently required.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research